Vanda Pharmaceuticals Croissance future
Future contrôle des critères 2/6
Vanda Pharmaceuticals devrait augmenter ses bénéfices et ses revenus de 62.6% et de 20.4% par an respectivement, tandis que le BPA devrait croître de croître de 64.9% par an.
Informations clés
62.6%
Taux de croissance des bénéfices
64.92%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.5% |
| Taux de croissance des recettes | 20.4% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 11 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • May 17
VNDA: Psychiatry Franchise And New Launches Will Drive Earnings Repricing
Analysts have adjusted the fair value estimate for Vanda Pharmaceuticals to $14.90 from $12.67, reflecting updated expectations for profitability, P/E assumptions, and the potential contribution from BYSANTI and other near-commercial assets highlighted in recent research. Analyst Commentary Recent Street research on Vanda Pharmaceuticals presents a mixed picture, with some analysts emphasizing upside from newly approved and near-commercial assets, while others are trimming targets as expectations and assumptions are recalibrated.Seeking Alpha • May 13
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
Summary Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price appreciation as of Tuesday's data. Earnings and cash flow trends remain weak, with persistent operating losses, high R&D costs, and no profitability expected until at least 2030. Technical analysis signals a neutral trend, but recent drug launches and upgraded revenue guidance provide a potential growth catalyst. The risk of cash burn was highlighted as well, with about 1.6 years of cash runway expected at current burn rates unless it improves soon. Read the full article on Seeking Alpha
Mise à jour du récit • Apr 28
VNDA: Psychiatry Franchise And Nereus Data Will Shape Balanced Future Prospects
Analysts have raised their average price target on Vanda Pharmaceuticals by $3, from $14 to $17, citing updated revenue models after BYSANTI's approval, expectations for growth in the psychiatry franchise, and potential upside from additional commercial and near-commercial assets. Analyst Commentary Recent research has highlighted a more constructive tone around Vanda Pharmaceuticals, with multiple firms publishing views that anchor on BYSANTI, the broader psychiatry franchise, and the company’s commercial portfolio.Mise à jour du récit • Apr 14
VNDA: Psychiatry Franchise And Nereus Opportunity Will Shape Balanced Future Upside
Analysts have raised their average price target for Vanda Pharmaceuticals to reflect updated expectations around the recently approved BYSANTI, ongoing prescriptions for Fanapt, and potential upside from Nereus in GLP-1 related vomiting, with current targets from recent research ranging from $17 to $24. Analyst Commentary Recent research has generally been constructive on Vanda Pharmaceuticals, with several firms assigning Buy ratings alongside price targets in the mid to high teens and low twenties.
Mise à jour du récit • Mar 31
VNDA: Psychiatry Franchise And GLP 1 Vomiting Opportunity Will Shape 2026 Outlook
Analysts have raised their fair value estimate for Vanda Pharmaceuticals to $24 from $22, reflecting updated models that incorporate the FDA approval of Bysanti, higher expectations for the psychiatry franchise, and emerging opportunities such as Nereus in GLP-1 related vomiting. Analyst Commentary Bullish analysts are leaning into Vanda's updated story around Bysanti, Fanapt, and newer assets, with several raising fair value assumptions and highlighting a broader psychiatry and gastrointestinal opportunity set.Mise à jour du récit • Mar 16
VNDA: Psychiatry Reliance Will Limit Upside Despite Recent Drug Approvals
Analysts have raised their average price targets for Vanda Pharmaceuticals into the mid to high teens in dollar terms, citing the recent FDA approval of Bysanti, updated revenue models for the psychiatry franchise, and potential upside from the Nereus program as key reasons for the change. Analyst Commentary Recent Street research around Vanda Pharmaceuticals has centered on the implications of Bysanti's FDA approval, the outlook for the psychiatry franchise, and the potential contribution of pipeline assets such as Nereus and tasimelteon.Mise à jour du récit • Mar 02
VNDA: Psychiatry Concentration Risk Will Drive A Cautious Forward Outlook
Analysts have lifted their average price target for Vanda Pharmaceuticals to a higher range of $17 to $24, citing updated revenue models that now include expected BYSANTI contributions and revised assumptions for its psychiatry franchise. Analyst Commentary Recent research has centered on the impact of BYSANTI and the broader psychiatry franchise on Vanda Pharmaceuticals, with updated revenue models now reflecting expected BYSANTI contributions and revised assumptions around prescription trends.Mise à jour du récit • Feb 16
VNDA: Jet Lag Setback Will Keep Focus On 2026 Earnings Outlook
Analysts kept their $22 price target for Vanda Pharmaceuticals unchanged, citing recent FDA feedback on tasimelteon for jet lag as a limited setback that was already excluded from their valuation assumptions. Analyst Commentary Bullish analysts frame the recent FDA feedback on tasimelteon for jet lag as a contained issue.Mise à jour du récit • Feb 02
VNDA: Jet Lag Setback Will Keep Focus On Imsidolimab BLA Milestone
Analysts have lifted their fair value estimate for Vanda Pharmaceuticals to $22 from $20, citing Street research that views the recent FDA decision on tasimelteon for jet lag as a limited setback that was not factored into prior valuation work. Analyst Commentary Bullish analysts frame the FDA decision on tasimelteon for jet lag as a limited setback rather than a thesis changer for Vanda Pharmaceuticals.Mise à jour du récit • Jan 19
VNDA: Imsidolimab Filing And Motion Sickness Approval Will Shape Balanced Outlook
Analysts have kept their fair value estimate for Vanda Pharmaceuticals steady at US$7.50, while modestly updating assumptions for the discount rate, revenue growth, profit margin, and future P/E after viewing the recent tasimelteon sNDA setback as a limited issue that was not central to their prior price target work. Analyst Commentary Street research commentary around Vanda Pharmaceuticals has framed the recent tasimelteon update as a limited issue for the equity story, with some firms explicitly stating that their valuation work did not depend on jet lag revenues for HETLIOZ.Mise à jour du récit • Jan 04
VNDA: Imsidolimab Milestones And Motion Sickness Launch Will Drive Balanced Outlook
Analysts have modestly raised their fair value estimate for Vanda Pharmaceuticals to approximately $7.50 from about $5.00 per share, citing improving milestone visibility tied to the anticipated imsidolimab BLA submission and a reassessment of long term earnings potential, even as revenue growth assumptions have become more tempered. Analyst Commentary Bearish analysts acknowledge that the clearer path toward an imsidolimab BLA filing has improved Vanda's long term earnings visibility, but they remain wary that the ultimate revenue contribution could fall short of current expectations.
Nouveau récit • Apr 24
New Indications And Pipeline Advances Will Strengthen Position
Expansion of Fanapt's sales and marketing efforts is expected to drive significant revenue growth through increased brand awareness and prescriber engagement.Seeking Alpha • Sep 05
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Summary Fanapt, approved for bipolar I disorder, faces significant competition from generics like Abilify, making it unlikely to drive substantial revenue growth. Ponvory, acquired from Janssen, faces similar competitive pressures, with generic versions of similar drugs dominating the multiple sclerosis market. Despite failing its primary endpoint in gastroparesis, Vanda is still pushing for regulatory approval for tradipitant, facing regulatory hurdles. Despite receiving two acquisition offers with a premium, Vanda rejected them, raising concerns about their cash management and future stock performance. Vanda's stock remains a hold due to cash strength, but limited product pipeline differentiation makes long-term growth prospects challenging. Read the full article on Seeking AlphaSeeking Alpha • Aug 08
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Summary Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operations. Vanda has disgruntled shareholders who may find creative ways to maximize shareholder value, despite a recent AGM failing to oust the unpopular Board of Directors and an existing poison pill. Retail shareholders can buy Vanda for less than the company's cash value, getting the potential benefit from the actions of activist shareholders for free. Read the full article on Seeking AlphaSeeking Alpha • Jun 18
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Summary Vanda Pharmaceuticals’ portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA’s upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA’s undervaluation and strategic value. VNDA trades below its cash value, with significant cash reserves and no debt, suggesting financial stability and growth potential. VNDA's diversified late-stage IP and substantial TAM make it a compelling investment despite the biotech and M&A risks. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Summary Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not significantly contribute to Vanda's bottom line as there are already several drugs approved for this indication. Despite a strong balance sheet, Vanda's future is heavily reliant on expanding existing drugs indications and new drug successes. Maintain "Hold" recommendation: Fanapt's bipolar indication is unlikely to significantly impact revenue; the company faces moderate-to-high risk. Read the full article on Seeking AlphaArticle d’analyse • Feb 15
Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) stock, leading do a rise in the share price...Seeking Alpha • Feb 13
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Summary Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share). Multiple FDA approvals, if forthcoming, in 2024 could prove to be material catalysts, perhaps highlighting that the company has operational assets beyond its cash. The market's current valuation of VNDA appears too pessimistic and a range of $5-10/share may be more reasonable, even assuming imperfect capital allocation. There could be further upside if drug approvals and operational performance go well in 2024. If things trend poorly, a valuation below $4/share is possible if operational performance is weak in 2024 and FDA approvals are not forthcoming. Read the full article on Seeking AlphaArticle d’analyse • Feb 10
Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong...Article d’analyse • Nov 11
News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
One thing we could say about the covering analyst on Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ) - they aren't...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 432 | -45 | -18 | 25 | 4 |
| 12/31/2027 | 356 | -62 | -65 | -44 | 5 |
| 12/31/2026 | 263 | -140 | -148 | -142 | 5 |
| 3/31/2026 | 218 | -240 | -137 | -127 | N/A |
| 12/31/2025 | 216 | -220 | -110 | -109 | N/A |
| 9/30/2025 | 212 | -84 | -83 | -82 | N/A |
| 6/30/2025 | 203 | -67 | -66 | -65 | N/A |
| 3/31/2025 | 201 | -44 | -59 | -56 | N/A |
| 12/31/2024 | 199 | -19 | -20 | -16 | N/A |
| 9/30/2024 | 191 | -16 | -123 | -18 | N/A |
| 6/30/2024 | 182 | -11 | -110 | -5 | N/A |
| 3/31/2024 | 178 | -5 | -115 | -11 | N/A |
| 12/31/2023 | 193 | 3 | -88 | 13 | N/A |
| 9/30/2023 | 212 | 12 | 26 | 26 | N/A |
| 6/30/2023 | 238 | 15 | 40 | 41 | N/A |
| 3/31/2023 | 257 | 16 | 59 | 60 | N/A |
| 12/31/2022 | 254 | 6 | 31 | 32 | N/A |
| 9/30/2022 | 258 | 6 | 49 | 49 | N/A |
| 6/30/2022 | 263 | 11 | 45 | 46 | N/A |
| 3/31/2022 | 266 | 18 | 59 | 59 | N/A |
| 12/31/2021 | 269 | 33 | 64 | 64 | N/A |
| 9/30/2021 | 268 | 34 | 56 | 57 | N/A |
| 6/30/2021 | 259 | 32 | 55 | 57 | N/A |
| 3/31/2021 | 253 | 32 | 60 | 62 | N/A |
| 12/31/2020 | 248 | 23 | 50 | 52 | N/A |
| 9/30/2020 | 241 | 19 | 41 | 42 | N/A |
| 6/30/2020 | 241 | 114 | 38 | 39 | N/A |
| 3/31/2020 | 237 | 117 | 34 | 35 | N/A |
| 12/31/2019 | 227 | 116 | N/A | 46 | N/A |
| 9/30/2019 | 219 | 122 | N/A | 51 | N/A |
| 6/30/2019 | 209 | 28 | N/A | 54 | N/A |
| 3/31/2019 | 197 | 22 | N/A | 38 | N/A |
| 12/31/2018 | 193 | 25 | N/A | 30 | N/A |
| 9/30/2018 | 184 | 13 | N/A | 18 | N/A |
| 6/30/2018 | 177 | 1 | N/A | 12 | N/A |
| 3/31/2018 | 171 | -5 | N/A | 5 | N/A |
| 12/31/2017 | 165 | -16 | N/A | -2 | N/A |
| 9/30/2017 | 159 | -14 | N/A | -7 | N/A |
| 6/30/2017 | 156 | -10 | N/A | -8 | N/A |
| 3/31/2017 | 150 | -13 | N/A | -9 | N/A |
| 12/31/2016 | 146 | -18 | N/A | -8 | N/A |
| 9/30/2016 | 140 | -32 | N/A | -7 | N/A |
| 6/30/2016 | 129 | -41 | N/A | -13 | N/A |
| 3/31/2016 | 121 | -42 | N/A | 2 | N/A |
| 12/31/2015 | 110 | -40 | N/A | 12 | N/A |
| 9/30/2015 | 93 | 45 | N/A | -1 | N/A |
| 6/30/2015 | 80 | 53 | N/A | -3 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: VNDA devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: VNDA devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: VNDA devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de VNDA ( 20.4% par an) devrait croître plus rapidement que le marché US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de VNDA ( 20.4% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de VNDA devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 05:14 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Vanda Pharmaceuticals Inc. est couverte par 18 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |